Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 12/2015

01-12-2015 | Literatur kommentiert

Körperstereotaxie und Lobektomie im randomisierten Vergleich beim NSCLC Stadium I – endlich Level-I-Evidenz?

Authors: Prof. Dr. Matthias Guckenberger, M.D., Dr. Nicolaus Andratschke

Published in: Strahlentherapie und Onkologie | Issue 12/2015

Login to get access

Auszug

Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy, for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637 …
Literature
1.
Scott WJ, Allen MS, Darling G, Meyers B, Decker PA, Putnam JB, McKenna RW, Landrenau RJ, Jones DR, Inculet RI et al (2010) Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. J Thorac Cardiovasc Surg 139:976–981. (discussion 981–973)
2.
Guckenberger M (2015) Stereotactic body radiotherapy in operable patients with stage I NSCLC: where is the evidence? Expert Rev Anticancer Ther. 15(5):525-530. doi:10.1586/14737140.2015.1023190
3.
Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, Jones DR, McKenna RJ, Landreneau RJ, Rusch VW et al (2011) Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 141:662–670CrossRefPubMed
4.
Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB (2001) The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 345:181–188CrossRefPubMed
5.
Cheung MC, Hamilton K, Sherman R, Byrne MM, Nguyen DM, Franceschi D, Koniaris LG (2009) Impact of teaching facility status and high-volume centers on outcomes for lung cancer resection: an examination of 13,469 surgical patients. Ann Surg Oncol 16:3–13CrossRefPubMed
6.
Luchtenborg M, Riaz SP, Coupland VH, Lim E, Jakobsen E, Krasnik M, Page R, Lind MJ, Peake MD, Moller H (2013) High procedure volume is strongly associated with improved survival after lung cancer surgery. J Clin Oncol 31:3141–3146CrossRefPubMed
7.
Guckenberger M, Allgauer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S et al (2013) Safety and efficacy of stereotactic body radiotherapy for stage i non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 8:1050–1058CrossRefPubMed
8.
Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD (2012) Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 84:1060–1070PubMedCentralCrossRefPubMed
9.
Su S, Scott WJ, Allen MS, Darling GE, Decker PA, McKenna RJ, Meyers BF (2014) Patterns of survival and recurrence after surgical treatment of early stage non-small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. J Thorac Cardiovasc Surg 147:747–752. (Discussion 752–743)CrossRefPubMed
10.
Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S (2012) Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 13:802–809CrossRefPubMed
11.
Zhang J, Yang F, Li B, Li H, Liu J, Huang W, Wang D, Yi Y, Wang J (2011) Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 81:e305–e316CrossRefPubMed
Metadata
Title
Körperstereotaxie und Lobektomie im randomisierten Vergleich beim NSCLC Stadium I – endlich Level-I-Evidenz?
Authors
Prof. Dr. Matthias Guckenberger, M.D.
Dr. Nicolaus Andratschke
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 12/2015
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0905-4

Other articles of this Issue 12/2015

Strahlentherapie und Onkologie 12/2015 Go to the issue

Letter to the Editor

Comment on Dornoff et al.: Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck

Original Article

Long-term outcome of moderate hypofractionated stereotactic radiotherapy for meningiomas

Letter to the Editor

Reply to: Comment on Dornoff et al.: re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck

Original Article

Radiotherapy for benign achillodynia

Original Article

Metformin influences progression in diabetic glioblastoma patients

Original Article

Comparison of CT number calibration techniques for CBCT-based dose calculation